Pune, India | January 14, 2026
Celltrion, Inc. unveiled a bold strategy to expand its drug pipeline and U.S. manufacturing operations at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Moreover, company leaders emphasized plans to accelerate innovation in cancer therapeutics. They also highlighted the importance of strengthening local production capacity. These strategic moves signal a long-term commitment to the United States and global healthcare growth.
At the conference’s Main Track event, Chief Executive Officer Jin Seok Seo and Senior Executive Vice President Hyuk Jae Lee delivered a comprehensive address showcasing the company’s evolving priorities. Consequently, they explained how Celltrion will leverage its antibody expertise to advance next-generation therapies. These therapies include antibody-drug conjugates (ADCs) and multi-specific antibodies (msAbs).
In their presentation titled “From Biosimilar Excellence to Next Gen Innovative Therapeutics,” Celltrion outlined plans to file up to 16 investigational new drug (IND) applications by 2028. Furthermore, the initiative reflects the company’s shift toward proprietary innovation. The ultimate goal is to improve outcomes for patients with unmet medical needs.
Specifically, the company’s pipeline will include up to ten ADC candidates and four msAbs. It also includes a recombinant protein and a peptide therapeutic. Meanwhile, Celltrion continues to pursue treatments for solid tumor cancers and other serious diseases with limited treatment options.
Three ADC candidates, CT P70, CT P71, and CT P73, received IND acceptance from the U.S. Food and Drug Administration (FDA) during 2025. Notably, CT P70 targets non-small cell lung cancer (NSCLC) and earned Fast Track designation. This designation enables more frequent regulator interactions. As a result, Celltrion strengthens its competitive edge in oncology innovation.
Celltrion’s msAb portfolio has likewise shown progress. For example, CT P72, a tetravalent bispecific antibody targeting HER2 and CD3, secured FDA IND approval. Thus, it reinforces the company’s commitment to precision oncology. These therapies engage immune mechanisms selectively. They also target cancer cells with high specificity.
“Celltrion has made remarkable progress and sees compelling opportunities ahead,” stated Seo. He additionally emphasized how the company’s drug pipeline reflects strategic innovation. Furthermore, he added that Celltrion aims to establish new care standards. In addition, it will deliver meaningful value to global patient communities.
Alongside clinical advancements, Celltrion shared concrete plans to scale U.S. manufacturing and research and development (R&D). The company completed the acquisition of a former Eli Lilly drug manufacturing facility in Branchburg, New Jersey. The site currently offers 66,000 liters of drug substance (DS) capacity. Additionally, it will expand to 132,000 liters by 2030. It will also incorporate drug product (DP) capabilities to support higher output.
Hyuk Jae Lee explained that expanding U.S. manufacturing enhances supply stability. It also mitigates tariff risks linked to international trade. Consequently, building robust local facilities allows Celltrion to compete more effectively. Furthermore, it ensures reliable access for U.S. patients.
“This acquisition underscores a pivotal step in strengthening our supply chain and solidifying our U.S. presence,” Lee said. Moreover, he noted that extended local capacity provides a foundation for deeper R&D collaborations. Therefore, the company anticipates improved partnerships and scientific growth.
Celltrion’s drug pipeline and manufacturing strategy reflect a dual focus on high-impact innovation and localized production resilience. In addition, the company reaffirmed its commitment to biosimilars. It plans to commercialize up to 18 products by 2030. By 2038, the company aims to have 41 products available. This ensures global accessibility and affordability of essential therapies.
Industry analysts noted that Celltrion’s presentation provided clarity and confidence for investors. In fact, the company showcased a clear roadmap for future growth. It blends scientific ambition with strong operational capabilities. Consequently, transparent communication of drug pipeline milestones and U.S. expansion plans demonstrates strategic focus. It also signals readiness for the next growth phase.
The acquisition of U.S. manufacturing assets aligns with industry trends toward onshore production. This reduces geopolitical risks and strengthens critical supply chains. Thus, Celltrion maintains a competitive edge in the global pharmaceutical market.
Patient advocates and healthcare stakeholders welcomed the company’s emphasis on high-need areas such as oncology. With ADCs and msAbs actively in development, Celltrion’s drug pipeline could expand treatment options. This benefits individuals facing challenging cancer diagnoses.
Looking forward, Celltrion will leverage its growing U.S. footprint to accelerate clinical transitions and regulatory interactions. Therefore, localizing production and research helps align with U.S. healthcare demands. Consequently, this approach enhances the company’s ability to deliver innovative therapies efficiently.
In summary, Celltrion’s announcement at the J.P. Morgan Healthcare Conference marked a pivotal moment in its evolution as a global biopharmaceutical leader. Ultimately, strategic investment in the drug pipeline and U.S. manufacturing positions the company to expand its global footprint. It also supports faster therapeutic advancements and better patient care worldwide.
